DUBLIN, April 23, 2015 /PRNewswire/ -- Jazz
Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will
report its 2015 first quarter financial results on Thursday, May 7, 2015, after the close of the
financial markets. Company management will host a live audio
webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m.
IST to discuss first quarter 2015 financial results and
provide a business and financial update.
Interested parties may access the live audio webcast via the
Investors & Media section of the Jazz Pharmaceuticals website
at www.jazzpharmaceuticals.com. Please connect to the website
prior to the start of the conference call to ensure adequate time
for any software downloads that may be necessary to listen to the
webcast. A replay of the webcast will be archived on the
website for one week.
Audio webcast/conference call:
U.S. Dial-In
Number: +1 877 415 3179
International Dial-In Number: +1 857 244 7322
Passcode: 74301034
A replay of the conference call will be available through
May 14, 2015 and accessible through
one of the following telephone numbers, using the passcode
below:
Replay U.S. Dial-In Number: +1 888 286 8010
Replay International Dial-In Number: +1 617 801 6888
Passcode: 39160618
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc
(Nasdaq: JAZZ) is an international biopharmaceutical company
focused on improving patients' lives by identifying, developing and
commercializing meaningful products that address unmet medical
needs. The company has a diverse portfolio of products and/or
product candidates with a focus in the areas of sleep and
hematology/oncology. In these areas, Jazz Pharmaceuticals
markets Xyrem® (sodium oxybate) oral solution and Erwinaze®
(asparaginase Erwinia chrysanthemi) in the U.S., and markets
Erwinase® and Defitelio® (defibrotide) in Europe and other countries outside the
U.S. For more information, please visit
www.jazzpharmaceuticals.com.